A case report with shock induced by tolvaptan in an elderly patient with congestive heart failure

RATIONALE: Tolvaptan (TLV) is a new vasopressin type 2 receptor antagonist effective in patients with heart failure (HF). Accumulating evidences have revealed that treatment with TLV does not alter the blood pressure significantly. PATIENT CONCERNS: An 84-year-old man was diagnosed with acute exacer...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhi-gang, Liu, Xin-min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943106/
https://www.ncbi.nlm.nih.gov/pubmed/29505505
http://dx.doi.org/10.1097/MD.0000000000008706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943106/
https://www.ncbi.nlm.nih.gov/pubmed/29505505
http://dx.doi.org/10.1097/MD.0000000000008706

Ejemplares similares